Capella BioScience

Capella Bioscience Limited engages in the discovery and development of monoclonal antibodies

Capella Bioscience Limited engages in the discovery and development of monoclonal antibodies (mAbs). It focuses on the employment of proprietary technologies to discover, develop, and commercialize medicines based on mAbs therapeutics for oncology, autoimmune, and other diseases independently, as well in collaboration with biotechnology and academic partners